
Do CDK4/6 inhibitors affect fertility and are they beneficial in premenopausal women?
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status

Positive patient-reported outcomes data expand on the efficacy benefits of trastuzumab deruxtecan and pembrolizumab
Two studies show that quality of life was maintained or improved with new treatments for advanced breast cancer

Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time

Perioperative survival after bilobectomy is worse than lobectomy
Although bilobectomy remains a valid procedure, comparatively high mortality rates indicate that cautious use and appropriate patient counselling is required

Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients

Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations

Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings

Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis

Patient-reported outcomes favour first-line three-drug combination in metastatic NSCLC
Health-related quality of life data from the POSEIDON study support previous efficacy findings for the benefits of a two-agent immunotherapy regimen plus chemotherapy over chemotherapy alone

Patient-reported outcomes are essential when their availability is prompt
Patient-reported outcomes provide important information for treatment decision-making but are not generally published alongside primary efficacy and safety data